<DOC>
	<DOC>NCT02291679</DOC>
	<brief_summary>The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic idiopathic constipation (CIC). The primary efficacy parameter is the percentage of patients in each dosing group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder.</brief_summary>
	<brief_title>Trial of Linaclotide in Patients With Chronic Idiopathic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Patient has completed a colonoscopy if one is needed according to the AGA criteria, with no clinically significant findings Patient has no clinically significant findings on a physical examination and clinical laboratory tests Patient meets protocol criteria for CIC: reports &lt; 3 bowel movements per week and reports one or more of the following during â‰¥ 25% of BMs: straining, lumpy or hard stools, sensation of incomplete evacuation Patient demonstrates continued chronic idiopathic constipation through Pretreatment Period Patient is compliant with daily IVRS (interactive voice response system) calls Patient has history of loose or watery stools Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS) Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility Patient has any protocolexcluded or clinically significant medical or surgical history that could confound the study assessments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>